Published in Brain on May 01, 1999
Neurophysiological Assessment in Patients With Multiple Sclerosis | NCT04997343
Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol (2014) 2.99
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 2.58
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol (2015) 2.23
MRI of the corpus callosum in multiple sclerosis: association with disability. Mult Scler (2010) 2.13
Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol (2013) 2.08
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology (2013) 2.06
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol (2014) 1.96
Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci (2008) 1.90
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry (2013) 1.60
Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci (2010) 1.59
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain (2015) 1.46
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord (2010) 1.34
Gait analysis methods: an overview of wearable and non-wearable systems, highlighting clinical applications. Sensors (Basel) (2014) 1.34
Automated vs. conventional tractography in multiple sclerosis: variability and correlation with disability. Neuroimage (2009) 1.27
Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS One (2012) 1.26
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol (2014) 1.18
The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure. J Neurol Neurosurg Psychiatry (2004) 1.17
Quantitative measures detect sensory and motor impairments in multiple sclerosis. J Neurol Sci (2011) 1.14
Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity. Mult Scler (2010) 1.14
Longitudinal scalar-on-functions regression with application to tractography data. Biostatistics (2013) 1.13
Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry. J Neurol Sci (2009) 1.11
Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry (2000) 1.10
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10
Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis. PLoS One (2014) 1.10
Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2005) 1.09
Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology (2011) 1.08
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol (2016) 1.08
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol (2015) 1.05
Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol (2014) 1.04
Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients. PLoS One (2013) 1.04
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry (2007) 1.01
A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis. Mult Scler (2011) 0.98
Long-term exercise improves functional impairment but not quality of life in multiple sclerosis. J Neurol (2005) 0.98
Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. J Neurol (2009) 0.98
The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics. Mult Scler Relat Disord (2012) 0.97
Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry (2006) 0.97
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol (2012) 0.97
Quality of life in multiple sclerosis. J Med Life (2011) 0.97
Assessing neuronal metabolism in vivo by modeling imaging measures. J Neurosci (2010) 0.97
Evaluating the progression of Friedreich ataxia and its treatment. J Neurol (2009) 0.96
Composite MRI scores improve correlation with EDSS in multiple sclerosis. Mult Scler (2010) 0.96
Is inflammation important in early PPMS? a longitudinal MRI study. J Neurol Neurosurg Psychiatry (2005) 0.95
Diffusion tensor imaging of the optic tracts in multiple sclerosis: association with retinal thinning and visual disability. J Neuroimaging (2011) 0.95
Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol (2005) 0.94
MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol (2009) 0.94
Activities-specific balance confidence in people with multiple sclerosis. Mult Scler Int (2012) 0.94
Functional MRI study of PASAT in normal subjects. MAGMA (2005) 0.93
Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol (2008) 0.93
Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry (2006) 0.92
Using perceptive computing in multiple sclerosis - the Short Maximum Speed Walk test. J Neuroeng Rehabil (2014) 0.92
The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool. J Vis Exp (2014) 0.92
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler (2012) 0.91
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. Medicine (Baltimore) (2011) 0.91
Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.91
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis. Int J MS Care (2014) 0.90
Motor fatigue measurement by distance-induced slow down of walking speed in multiple sclerosis. PLoS One (2012) 0.90
Interferon beta and glatiramer acetate therapy. Neurotherapeutics (2013) 0.90
The development of ICF Core Sets for multiple sclerosis: results of the International Consensus Conference. J Neurol (2011) 0.89
Relating brain damage to brain plasticity in patients with multiple sclerosis. Neurorehabil Neural Repair (2012) 0.89
Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging. J Neurol (2008) 0.88
Functional magnetic resonance imaging movers and shakers: does subject-movement cause sampling bias? Hum Brain Mapp (2012) 0.88
Predicting falls in people with multiple sclerosis: fall history is as accurate as more complex measures. Mult Scler Int (2013) 0.88
Hand function in multiple sclerosis: force coordination in manipulation tasks. Clin Neurophysiol (2008) 0.88
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology (2012) 0.87
Tract-specific quantitative MRI better correlates with disability than conventional MRI in multiple sclerosis. J Neurol (2012) 0.87
A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol (2010) 0.86
Can we overcome the 'clinico-radiological paradox' in multiple sclerosis? J Neurol (2012) 0.86
Occupational attainment as a marker of cognitive reserve in multiple sclerosis. PLoS One (2012) 0.86
The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurol (2015) 0.86
N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J Neurol (2007) 0.85
Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Mult Scler (2009) 0.85
Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci (2011) 0.85
Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS). Health Qual Life Outcomes (2010) 0.85
Composite biomarkers for assessing Duchenne muscular dystrophy: an initial assessment. Pediatr Neurol (2014) 0.85
Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. J Neurol (2008) 0.84
Third ventricular enlargement in early stages of multiple sclerosis is a predictor of motor and neuropsychological deficits: a cross-sectional study. BMJ Open (2013) 0.84
Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial. Trials (2013) 0.84
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One (2013) 0.84
Correlations between MRI and Information Processing Speed in MS: A Meta-Analysis. Mult Scler Int (2014) 0.83
Preservation of motor skill learning in patients with multiple sclerosis. Mult Scler (2010) 0.83
Dynamics of saccade parameters in multiple sclerosis patients with fatigue. J Neurol (2012) 0.83
Personality traits in women with multiple sclerosis: discrepancy in patient/partner report and disease course. J Psychosom Res (2008) 0.82
Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. Brain (2015) 0.82
Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. Neuroimage (2013) 0.82
Fractional anisotropy and mean diffusivity in the corpus callosum of patients with multiple sclerosis: the effect of physiotherapy. Neuroradiology (2011) 0.82
Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery. BMC Neurol (2011) 0.82
Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy. BMC Neurol (2004) 0.82
Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. Drugs (2015) 0.82
Topography of brain sodium accumulation in progressive multiple sclerosis. MAGMA (2013) 0.81
Reliable measurements of brain atrophy in individual patients with multiple sclerosis. Brain Behav (2016) 0.81
Multiple sclerosis: monitoring long-term treatments in multiple sclerosis. Nat Rev Neurol (2010) 0.81
Only low frequency event-related EEG activity is compromised in multiple sclerosis: insights from an independent component clustering analysis. PLoS One (2012) 0.81
Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int (2014) 0.81
Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS One (2012) 0.81
Assessment set for evaluation of clinical outcomes in multiple sclerosis: psychometric properties. Patient Relat Outcome Meas (2012) 0.81
Responsiveness of walking-based outcome measures after multiple sclerosis relapses following steroid pulses. Med Sci Monit (2011) 0.81
Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis. J Neuroinflammation (2014) 0.81
A comparison of three measures of upper limb function in Friedreich ataxia. J Neurol (2009) 0.81
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
Multiple sclerosis. N Engl J Med (2000) 12.69
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (2010) 11.55
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol (2007) 7.30
Conceptual processing during the conscious resting state. A functional MRI study. J Cogn Neurosci (1999) 6.67
Structural basis of cell-cell adhesion by cadherins. Nature (1995) 6.56
Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell (1991) 6.28
Spectrographic data concerning vitamin A and liver oils. Biochem J (1931) 6.14
Mechanism of action and development of resistance to a new amidino penicillin. J Bacteriol (1974) 5.47
Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell (1992) 5.29
X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science (1999) 4.78
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Human brain language areas identified by functional magnetic resonance imaging. J Neurosci (1997) 4.15
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Altered electrical properties in Drosophila neurons developing without synaptic transmission. J Neurosci (2001) 3.80
The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler (1999) 3.71
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain (2001) 3.51
A health-related quality of life measure for multiple sclerosis. Qual Life Res (1995) 3.46
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 3.43
Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. Trends Parasitol (2006) 3.34
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain (1980) 3.27
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
The crystal structure of dimeric kinesin and implications for microtubule-dependent motility. Cell (1997) 3.17
Penicillin-sensitive enzymes and penicillin-binding components in bacterial cells. Ann N Y Acad Sci (1974) 3.16
Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn (1992) 3.14
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol (1995) 3.06
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology (2005) 2.95
Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci U S A (1985) 2.93
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol (2001) 2.75
Coma in the Wernicke-Korsakoff syndrome. Lancet (1978) 2.74
Determination of language dominance using functional MRI: a comparison with the Wada test. Neurology (1996) 2.71
Language processing is strongly left lateralized in both sexes. Evidence from functional MRI. Brain (1999) 2.71
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66
An activating mutation of AKT2 and human hypoglycemia. Science (2011) 2.60
Structure of a cephalosporin synthase. Nature (1998) 2.59
Criteria for the clinical diagnosis of multiple sclerosis. Neurology (1976) 2.54
Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 2.41
Antineutrophil cytoplasmic antibodies, cystic fibrosis, and infection. Lancet (1991) 2.41
Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry (1998) 2.40
La Crosse encephalitis in children. N Engl J Med (2001) 2.38
Corticosteroid-induced suppression of the hypothalamo-pituitary-adrenal axis: observations on patients given oral corticosteroids for rheumatoid arthritis. Q J Med (1967) 2.38
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology (2007) 2.32
Vasopressin administration facilitates fluid removal during hemodialysis. Kidney Int (2006) 2.23
Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol (1989) 2.23
Automation of sample mounting for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2006) 2.22
The pathophysiology of HOX genes and their role in cancer. J Pathol (2005) 2.18
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology (1998) 2.16
Increase of oleic acid in erythrocytes associated with malignancies. Br Med J (Clin Res Ed) (1985) 2.15
CNS aquaporin-4 autoimmunity in children. Neurology (2008) 2.10
A NEW METHOD FOR THE GENERATION AND USE OF FOCUSED ULTRASOUND IN EXPERIMENTAL BIOLOGY. J Gen Physiol (1942) 2.08
Neuropsychology of multiple sclerosis: a critical review. J Clin Exp Neuropsychol (1986) 2.02
Comparison of ultrasound measurements at the heel between adults with mental retardation and control subjects. Bone (1998) 1.97
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol (1998) 1.97
Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology (1980) 1.95
During infection of epithelial cells Salmonella enterica serovar Typhimurium undergoes a time-dependent transcriptional adaptation that results in simultaneous expression of three type 3 secretion systems. Cell Microbiol (2007) 1.94
Multiple sclerosis: a comparison of the latent periods of different populations. Neuroepidemiology (1993) 1.94
Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol (2001) 1.91
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain (2000) 1.89
Neural systems underlying the recognition of familiar and newly learned faces. J Neurosci (2000) 1.87
Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry (1998) 1.84
Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 1.83
Acute effects of ambient inhalable particles in asthmatic and nonasthmatic children. Am J Respir Crit Care Med (1998) 1.81
Eight-year follow-up study of brain atrophy in patients with MS. Neurology (2002) 1.78
Can medial temporal lobe regions distinguish true from false? An event-related functional MRI study of veridical and illusory recognition memory. Proc Natl Acad Sci U S A (2001) 1.76
Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. J Biol Chem (2000) 1.76
Functional magnetic resonance imaging of human auditory cortex. Ann Neurol (1994) 1.76
Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology (2010) 1.75
Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology (2003) 1.73
Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem (1999) 1.73
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol (1997) 1.72
Characterization of the ABA-deficient tomato mutant notabilis and its relationship with maize Vp14. Plant J (1999) 1.72
The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials. Mult Scler (2002) 1.71
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain (1998) 1.71
A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology (2007) 1.70
Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia (2000) 1.70
Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain (1998) 1.68
Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol (1997) 1.66
Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res (1988) 1.66